# Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）

> **NCT07242443** · PHASE4 · NOT_YET_RECRUITING · sponsor: **First People's Hospital of Hangzhou** · enrollment: 240 (estimated)

## Conditions studied

- HELICOBACTER PYLORI INFECTIONS

## Interventions

- **DRUG:** Tegoprazan 50 mg
- **DRUG:** Amoxicillin 1 g TID
- **DRUG:** Amoxicillin 1.5 g BID

## Key facts

- **NCT ID:** NCT07242443
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07242443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07242443, "Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07242443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*